Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Role of TIM-3 in ovarian cancer.

Literature DB >> 28357631

Role of TIM-3 in ovarian cancer.

Y Xu¹, H Zhang², Y Huang³, X Rui³, F Zheng³.

Abstract

Evidences have suggested that immunotherapy for ovarian cancer is effective. Immune checkpoints have emerged in the field of cancer immunotherapy. Multiple studies have shown negative regulation of TIM-3 expression on CD4+ and CD8+ T cells and other immunocytes. Overexpression of TIM-3 in innate immune cells has been found in certain types of tumor. The blockade of TIM-3 leads to sustained anti-tumor reactions. TIM-3 plays an inhibitive role for immunity in ovarian cancer. TIM-3 is involved in the development of various subtypes of ovarian cancer and thus has the potential to be a therapeutic target for treatment of ovarian cancer.

Entities: Disease Gene

Keywords: Blockade; Ovarian cancer; TIM-3

Mesh：

Substances：

Year: 2017 PMID： 28357631 DOI： 10.1007/s12094-017-1656-8

Source DB: PubMed Journal: Clin Transl Oncol ISSN： 1699-048X Impact factor: 3.405

50 in total

1. Allograft rejection is restrained by short-lived TIM-3+PD-1+Foxp3+ Tregs.

Authors: Shipra Gupta; Thomas B Thornley; Wenda Gao; Rafael Larocca; Laurence A Turka; Vijay K Kuchroo; Terry B Strom
Journal: J Clin Invest Date: 2012-06-11 Impact factor: 14.808

2. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease.

Authors: Laurent Monney; Catherine A Sabatos; Jason L Gaglia; Akemi Ryu; Hanspeter Waldner; Tatyana Chernova; Stephen Manning; Edward A Greenfield; Anthony J Coyle; Raymond A Sobel; Gordon J Freeman; Vijay K Kuchroo
Journal: Nature Date: 2002-01-31 Impact factor: 49.962

Review 3. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family.

Authors: Hélène Bour-Jordan; Jonathan H Esensten; Marc Martinez-Llordella; Cristina Penaranda; Melanie Stumpf; Jeffrey A Bluestone
Journal: Immunol Rev Date: 2011-05 Impact factor: 12.988

4. Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade.

Authors: Ines Pires da Silva; Anne Gallois; Sonia Jimenez-Baranda; Shaukat Khan; Ana C Anderson; Vijay K Kuchroo; Iman Osman; Nina Bhardwaj
Journal: Cancer Immunol Res Date: 2014-02-11 Impact factor: 11.151

Review 5. HMGB1 and RAGE in inflammation and cancer.

Authors: Gary P Sims; Daniel C Rowe; Svend T Rietdijk; Ronald Herbst; Anthony J Coyle
Journal: Annu Rev Immunol Date: 2010 Impact factor: 28.527

6. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation.

Authors: Edward Y Woo; Heidi Yeh; Christina S Chu; Katia Schlienger; Richard G Carroll; James L Riley; Larry R Kaiser; Carl H June
Journal: J Immunol Date: 2002-05-01 Impact factor: 5.422

7. Taming dendritic cells with TIM-3: another immunosuppressive strategy used by tumors.

Authors: Jaina Patel; Erica N Bozeman; Periasamy Selvaraj
Journal: Immunotherapy Date: 2012-12 Impact factor: 4.196

8. Tim-3 on peripheral CD4⁺ and CD8⁺ T cells is involved in the development of glioma.

Authors: Song Han; Sizhe Feng; Lunshan Xu; Weiwei Shi; Xuhui Wang; Hao Wang; Chunyong Yu; Tao Dong; Minhui Xu; Guobiao Liang
Journal: DNA Cell Biol Date: 2014-02-10 Impact factor: 3.311

9. Nivolumab plus ipilimumab in advanced melanoma.

Authors: Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal: N Engl J Med Date: 2013-06-02 Impact factor: 91.245

10. Decreased galectin-9 and increased Tim-3 expression are related to poor prognosis in gastric cancer.

Authors: Jing Jiang; Mei-Shan Jin; Fei Kong; Donghui Cao; Hong-Xi Ma; Zhifang Jia; Yin-Ping Wang; Jian Suo; Xueyuan Cao
Journal: PLoS One Date: 2013-12-10 Impact factor: 3.240

5 in total

Review 1. Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1.

Authors: Laure Chardin; Alexandra Leary
Journal: Front Oncol Date: 2021-12-13 Impact factor: 6.244

2. Landscape of Immune Microenvironment in Epithelial Ovarian Cancer and Establishing Risk Model by Machine Learning.

Authors: Shi-Yi Liu; Rong-Hui Zhu; Zi-Tao Wang; Wei Tan; Li Zhang; Yan-Qing Wang; Fang-Fang Dai; Meng-Qin Yuan; Ya-Jing Zheng; Dong-Yong Yang; Fei-Yan Wang; Shu Xian; Juan He; Yu-Wei Zhang; Ma-Li Wu; Zhi-Min Deng; Min Hu; Yan-Xiang Cheng; Ye-Qiang Liu
Journal: J Oncol Date: 2021-08-26 Impact factor: 4.375

3. The mechanism of LncRNA01977 in lung adenocarcinoma through the SDF-1/CXCR4 pathway.

Authors: Xiao-Rong Lai; Chang-Li Wang; Fei-Zhang Qin
Journal: Transl Cancer Res Date: 2022-03 Impact factor: 1.241

4. Serum T Cell Immunoglobulin Mucin 3 Predicts Worse Prognosis in Hepatocellular Carcinoma Patients Undergoing Transcatheter Arterial Chemoembolization.

Authors: Jun Li; Jing Wang
Journal: Med Sci Monit Date: 2022-07-21

5. ALOX5AP Predicts Poor Prognosis by Enhancing M2 Macrophages Polarization and Immunosuppression in Serous Ovarian Cancer Microenvironment.

Authors: Xiang Ye; Limei An; Xiangxiang Wang; Chenyi Zhang; Wenqian Huang; Chenggong Sun; Rongrong Li; Hanlin Ma; Hongyan Wang; Min Gao
Journal: Front Oncol Date: 2021-05-19 Impact factor: 6.244

5 in total